Q-omics provides the consensus-scored C4A-AS1 profile across patient tissues and cancer cell-line models. C4A-AS1 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, C4A-AS1 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, C4A-AS1 RNA expression shows 1,817 significant gene co-expression associations, with the highest sampling consensus in MESO. Together, these results highlight PAAD, LIHC, and MESO as cancer lineages where C4A-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C4A-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C4A-AS1 survival associations across molecular data types. C4A-AS1 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C4A-AS1 RNA expression–survival associations across cancer types. High C4A-AS1 expression shows unfavorable associations in PAAD, KIRP, BLCA, SKCM, CESC and PCPG. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify PAAD as the clearest survival context for C4A-AS1 RNA expression.
This table summarizes C4A-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for C4A-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C4A-AS1 shows higher tumor expression in LIHC. The LIHC box plot shows higher C4A-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .033).
This table shows molecular features associated with C4A-AS1 in patient tissues and cancer cell lines. In patient samples, C4A-AS1 shows the broadest associations at the RNA and protein expression levels, with MESO recurring as the lineage with the largest associated feature set.
